Science Daily -
29 Jul 2021 20:34
Researchers report the identification of a new target for the PARP inhibitor drug talazoparib and show that combination treatment with talazoparib and the WEE1 inhibitor adavosertib results in enhanced anti-cancer effects.
Share this Article